Chemoablation for Low-Grade Bladder Cancer

The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.

Trial Details

NCT ID
NCT07019220
Phase
PHASE2
Sponsor
Ekaterina Laukhtina
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • Gemcitabine
Locations (sample)
  • Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of providing documented informed consent will be enrolled in this study
  • Diagnosis of a recurrent tumor and a history of TaLG BCa or diagnosis of primary TaLG BCa histologically confirmed by cold cup biopsy at screening …
  • On screening cystoscopy: Diameter of the largest lesion ≤15mm
  • Number of lesions ≤5

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →